Peregrine Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Peregrine Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.4M	Buy	753,495 +33,033	+5%	+$299K	0.24%	133
2026 Q1	$6.1M	Buy	720,462 +149,359	+26%	+$1.42M	0.23%	135
2025 Q4	$6.93M	Sell	571,103 -46,416	-8%	-$564K	0.21%	135
2025 Q3	$7.22M	Sell	617,519 -244,443	-28%	-$2.92M	0.22%	130
2025 Q2	$8M	Buy	861,962 +14,494	+2%	+$113K	0.24%	114
2025 Q1	$6.21M	Buy	+847,468	New	+$6.51M	0.21%	145

Other funds holding OCUL

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

ELI

Empire Life Investments Toronto, Ontario, Canada $1.79B AUM 38.49% 1-Year Est. Return

EOJOAM

E. Ohman J:or Asset Management Stockholm, Sweden $4.3B AUM 29.55% 1-Year Est. Return

WesBanco Bank Wheeling, West Virginia $4.02B AUM 32.62% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

KIA

Kraematon Investment Advisors Braintree, Massachusetts $134M AUM 29.42% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

Courier Capital Buffalo, New York $2B AUM 24.36% 1-Year Est. Return

Peregrine Capital Management's OCUL Position: Q2 2026 in Review

Peregrine Capital Management increased its Ocular Therapeutix (OCUL) stake by 4.6% in Q2 2026, buying an estimated $299K and bringing the position to 753,495 shares worth $7.4M. The position accounts for 0.24% of the portfolio, ranked #133.

Peregrine Capital Management first reported a position in OCUL in Q1 2025 and has held it in 6 quarters since. The position peaked at $8M in Q2 2025. 48 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

Peregrine Capital Management held 753,495 shares of Ocular Therapeutix worth $7.4M as of Q2 2026.
Peregrine Capital Management bought 33,033 Ocular Therapeutix shares in Q2 2026, an estimated $299K.
Ocular Therapeutix made up 0.24% of Peregrine Capital Management's portfolio in Q2 2026, its #133 holding.
Peregrine Capital Management first reported a position in Ocular Therapeutix in Q1 2025 and has held it in 6 quarters since.
Peregrine Capital Management's Ocular Therapeutix position peaked at $8M in Q2 2025.
48 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Peregrine Capital Management's 13F filing for Q2 2026, filed 17 Jul 2026.